B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

TRPC6

MOLECULAR TARGET

transient receptor potential cation channel subfamily C member 6

UniProt: Q9Y210NCBI Gene: 722515 compounds

TRPC6 (transient receptor potential cation channel subfamily C member 6) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting TRPC6

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Hyoscyamine1.393
2Carvedilol1.393
3Propantheline1.393
4Methylene Blue1.102
5Hexachlorophene1.102
6Promazine1.102
7Promethazine1.102
8propionylpromazine hydrochloride1.102
9Thioridazine1.102
10triflupromazine hydrochloride1.102
11Arachidonic Acid0.691
12Duloxetine Hydrochloride0.691
13Amoxapine0.691
14Fluspirilene0.691
15Lysophosphatidylcholines Derivatives of PHOSPHATIDYLCHOLINES obtained by their partial hydrolysis which removes0.691

About TRPC6 as a Drug Target

TRPC6 (transient receptor potential cation channel subfamily C member 6) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented TRPC6 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

TRPC6 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.